* Biocon Group reported a strong Q2 FY26 performance with operating revenue at ₹4,296 crores, up 20% year-on-year, driven by double-digit growth in Biosimilars and Generics. Core EBITDA grew 23% to ₹1,218 crores with a 28% margin, and profit before tax (excluding exceptionals) rose 153% to ₹183 crores. * The company strengthened its balance sheet by settling structured debt obligations with Goldman Sachs and Kotak from QIP proceeds and executing an agreement with Edelweiss for an exit by January 31, 2026. This is expected to result in annual interest cost savings of around ₹300 crores from FY27. * Biocon successfully launched five biosimilar products: bUstekinumab (Yesintek), bAspart, bBevacizumab, and bAflibercept across geographies, with an imminent launch of bDenosumab. U.S. FDA approval for bDenosumab was also achieved, alongside a license agreement with Amgen. * A pioneering partnership with the government of California through Civica Inc. was formed to supply affordable insulin glargine under the CalRx initiative. * Biosimilars Segment: Revenue grew 25% year-on-year to ₹2,721 crores, with EBITDA growing over 40% to ₹669 crores, and an EBITDA margin of 25%. Yesintek gained strong commercial traction in the U.S. with over 70% commercial formulary listings. The interchangeable biosimilar Aspart was successfully launched. * Generics Segment: Revenue increased 24% year-on-year to ₹774 crores. Global filings for Semaglutide (gOzempic) commenced. The new oral solid dosage manufacturing facility in Cranbury, New Jersey, was inaugurated, and a U.S. FDA GMP inspection concluded with one minor observation. EBITDA stood at ₹43 crores, an improvement over the previous year and quarter, driven by new launches like Liraglutide and Sacubitril/Valsartan. * CRDMO Segment (Syngene): Revenue was ₹911 crores, up 2% year-on-year, with an EBITDA of ₹215 crores and a 23% margin. Syngene secured its first global Phase III clinical trial and expanded its clinical trials footprint globally. It is also expanding its biologic facility by adding a GMP bioconjugation suite. * Management expects performance in the second half of the fiscal year to strengthen further for the Generics business and anticipates continued improvement in profitability for the overall group in the quarters ahead. * The FDA's revised guidance on comparative efficacy trials is seen as a positive, reducing development costs and time, benefiting established players like Biocon in expanding their portfolio faster.
